Passive immunization against Pseudomonas with a ribosomal vaccine-induced immune serum and immunoglobulin fractions
- PMID: 106013
- PMCID: PMC414194
- DOI: 10.1128/iai.23.2.509-521.1979
Passive immunization against Pseudomonas with a ribosomal vaccine-induced immune serum and immunoglobulin fractions
Abstract
Passive protection of mice against Pseudomonas aeruginosa using specific antisera and immunoglobulin fractions induced by immunizing rabbits with a ribosomal vaccine is reported. The results demonstrated that protection by the ribosomal vaccine against challenge with live organisms can be serum mediated. Previous work has shown that the vaccine can be separated into two components on the basis of molecular weight and that both higher (peak A)- and lower (peak B)-molecular-weight fractions were capable of inducing active immunity in mice. The present report indicates that both fractions are also capable of eliciting the production of mouse-protective antibody in rabbits. Agar gel diffusion with antisera to peaks A and B or unfractionated vaccine indicated a common antigenic component among them in addition to an extra antigen in unfractionated vaccine not present in peak B. Passive hemagglutination with antisera to peaks A and B demonstrated high-titer agglutinating antibody only with antiserum to peak A when a method of erythrocyte sensitization for lipopolysaccharide antigens was used. Also, passive hemagglutination was greatly inhibited by small amounts of lipopolysaccharide prepared from the same organism from which the vaccine was made. Both antisera to peaks A and B fixed complement with either A or B antigens. Antisera to peaks A and B, when reacted with peak B antigen, had about the same complement fixation titer (as determined by a quantitative complement fixation test). However, when peak A antigen was used, antiserum to peak A had about twice the complement fixation titer that antiserum to peak B had. These results are consistent with previous observations which suggest that the ribosomal vaccine contains lipopolysaccharide in addition to an unidentified immunogenic principle associated with ribosomes. Furthermore, this immunogen was present in both peaks A and B, but detectable amounts of lipopolysaccharide were present only in peak A. The relative importance of the immunoglobulin G (IgG) and IgM classes of antibodies was also compared. The results indicated that both IgG and IgM isolated from immune rabbit serum are protective in mice. Only IgG precipitated with the vaccine in agar gel diffusion, but both IgG and IgM were active in passive hemagglutination and in complement fixation. The passive hemagglutination titer of the IgM was higher than that of the IgG, but the complement fixation titer of the IgG was higher than that of the IgM. The mouse-protective capability of the IgG and IgM was about the same.
Similar articles
-
Glycolipoprotein from Pseudomonas aeruginosa as a protective antigen against P. aeruginosa infection in mice.Infect Immun. 1977 Nov;18(2):304-9. doi: 10.1128/iai.18.2.304-309.1977. Infect Immun. 1977. PMID: 411754 Free PMC article.
-
Specificity of the protective response induced by the slime layer of Pseudomonas aeruginosa.J Hyg (Lond). 1974 Aug;73(1):75-84. doi: 10.1017/s002217240002386x. J Hyg (Lond). 1974. PMID: 4213979 Free PMC article.
-
Pseudomonas ribosomal vaccines: preparation, properties, and immunogenicity.Infect Immun. 1978 Jul;21(1):76-86. doi: 10.1128/iai.21.1.76-86.1978. Infect Immun. 1978. PMID: 101464 Free PMC article.
-
The prophylactic effects of human IgG derived from sera containing high anti-PcrV titers against pneumonia-causing Pseudomonas aeruginosa.Hum Vaccin Immunother. 2016 Nov;12(11):2833-2846. doi: 10.1080/21645515.2016.1209280. Epub 2016 Jul 25. Hum Vaccin Immunother. 2016. PMID: 27454613 Free PMC article.
-
Pseudomonas aeruginosa antigens as potential vaccines.FEMS Microbiol Rev. 1997 Nov;21(3):243-77. doi: 10.1111/j.1574-6976.1997.tb00353.x. FEMS Microbiol Rev. 1997. PMID: 9451816 Review.
Cited by
-
Polyvalent antisera to Pseudomonas ribosomal vaccines: protection of mice against clinically isolated strains.Infect Immun. 1980 Aug;29(2):489-93. doi: 10.1128/iai.29.2.489-493.1980. Infect Immun. 1980. PMID: 6783532 Free PMC article.
-
Opsonization and phagocytosis of Haemophilus influenzae type B organisms by mouse polymorphonuclear leucocytes and antiribosomal serum.Br J Exp Pathol. 1983 Jun;64(3):268-76. Br J Exp Pathol. 1983. PMID: 6603862 Free PMC article.
-
Cell-mediated immunity following experimental vaccinations with Candida albicans ribosomes.Mycopathologia. 1983 Nov 25;83(3):161-8. doi: 10.1007/BF00437023. Mycopathologia. 1983. PMID: 6366570
-
Exhaustion of bacteria-specific CD4 T cells and microbial translocation in common variable immunodeficiency disorders.J Exp Med. 2014 Sep 22;211(10):2033-45. doi: 10.1084/jem.20140039. Epub 2014 Sep 15. J Exp Med. 2014. PMID: 25225461 Free PMC article.
-
Ribonuclease-sensitive ribosomal vaccine of Pseudomonas aeruginosa.Infect Immun. 1980 Jan;27(1):204-10. doi: 10.1128/iai.27.1.204-210.1980. Infect Immun. 1980. PMID: 6153637 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources